Viva Biotech’s 2026 interim results show AI‑driven drug R&D and CDMO manufacturing lifting revenue 21% year‑on‑year
Executive summary: Viva Biotech announced its 2026 interim results, reporting revenue of RMB1,006.5 million (+21% YoY) and gross profit of RMB341.7 million (+0.7% YoY) with a 34% margin, highlighting AI‑sparked drug R&D and accelerated CDMO manufacturing as growth drivers. The outcome demonstrates that AI applications are contributing to top‑line expansion in the biotech contract manufacturing sector, signaling a potential shift in how R&D efficiency translates into revenue.
Who is involved: Viva Biotech (Hong Kong‑listed biotech firm), its AI‑enabled drug discovery team, CDMO customers, and shareholders.
Likely next: The firm is expected to continue investing in AI tools for drug pipelines, expand CDMO capacity in the second half of 2026, and report further earnings updates in November 2026.
The company reported revenue of RMB1,006.5 million for the six months ended June 2026, up 21% from a year earlier, while gross profit rose only 0.7% to RMB341.7 million, leaving the margin steady at 34%. Management attributed the top‑line growth to the integration of artificial intelligence in drug discovery and a faster ramp‑up of commercial manufacturing services for external clients. The results suggest that AI adoption is beginning to translate into tangible sales gains for biotech CDMO operators, though profitability remains modest.
Timeline
- — Viva Biotech Announces Its 2026 Interim Results: AI Sparks New Paradigm in Drug R&D, CDMO Commercial Manufacturing Accelerates Revenue Growth (PR Newswire)
- — Scinai Reports First Half 2026 Corporate Highlights and Results with Spotlight on Growing CDMO Momentum (PR Newswire)
Analysis — what this means
Sectors affected
- Biotech contract manufacturing (CDMO)
- AI‑enabled drug discovery
Key entities
Sources
- Viva Biotech Announces Its 2026 Interim Results: AI Sparks New Paradigm in Drug R&D, CDMO Commercial Manufacturing Accelerates Revenue Growth — PR Newswire
- Scinai Reports First Half 2026 Corporate Highlights and Results with Spotlight on Growing CDMO Momentum — PR Newswire